HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anthony Letai Selected Research

Tumor Biomarkers (Tumor Markers)

1/2019Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Anthony Letai Research Topics

Disease

79Neoplasms (Cancer)
01/2023 - 09/2002
17Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/2024 - 10/2012
13Leukemia
01/2022 - 11/2009
9B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
10/2023 - 01/2007
9B-Cell Lymphoma (Lymphoma, B Cell)
12/2022 - 08/2012
9Lymphoma (Lymphomas)
01/2021 - 04/2003
9Breast Neoplasms (Breast Cancer)
01/2021 - 10/2008
7Hematologic Neoplasms (Hematological Malignancy)
01/2023 - 01/2017
5Multiple Myeloma
12/2022 - 11/2005
5Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2019 - 02/2008
4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
01/2022 - 04/2013
4Lung Neoplasms (Lung Cancer)
01/2018 - 12/2007
4Carcinogenesis
05/2014 - 01/2008
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021 - 10/2012
3Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
10/2020 - 08/2012
3B-Cell Leukemia (Leukemia, B Cell)
10/2016 - 01/2007
2Graft vs Host Disease (Graft-Versus-Host Disease)
01/2024 - 09/2014
2Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2024 - 12/2021
2Carcinoma (Carcinomatosis)
10/2021 - 11/2016
2Non-Hodgkin Lymphoma (Lymphosarcoma)
02/2021 - 09/2015
2Triple Negative Breast Neoplasms
01/2021 - 11/2020
2Infections
01/2020 - 01/2018
2Thrombocytopenia (Thrombopenia)
01/2020 - 08/2013
1Malignant Mesothelioma
01/2023
1Waldenstrom Macroglobulinemia (Macroglobulinemia)
12/2022
1Aneuploidy (Aneuploid)
12/2020
1Nausea
01/2020
1Neutropenia
01/2020
1Febrile Neutropenia
01/2020
1Ovarian Neoplasms (Ovarian Cancer)
11/2019
1Wilms Tumor (Wilm's Tumor)
01/2019

Drug/Important Bio-Agent (IBA)

40Proteins (Proteins, Gene)FDA Link
12/2022 - 04/2003
27venetoclaxIBA
01/2024 - 01/2013
6Biomarkers (Surrogate Marker)IBA
01/2019 - 09/2012
6Peptides (Polypeptides)IBA
01/2018 - 09/2002
6ABT-737IBA
08/2012 - 06/2005
5Azacitidine (5 Azacytidine)FDA Link
01/2024 - 01/2019
5navitoclaxIBA
01/2021 - 08/2013
5Apoptosis Regulatory ProteinsIBA
01/2021 - 11/2009
4Drug CombinationsIBA
02/2024 - 01/2021
3S63845IBA
01/2021 - 12/2020
3Estrogen ReceptorsIBA
01/2021 - 01/2013
3Phosphotransferases (Kinase)IBA
01/2018 - 12/2017
3Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2018 - 12/2007
2CaspasesIBA
01/2023 - 12/2022
2ChromatinIBA
01/2022 - 01/2021
2RNA (Ribonucleic Acid)IBA
01/2022 - 01/2021
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2022 - 06/2014
2Cyclin-Dependent Kinases (cdk Proteins)IBA
01/2022 - 01/2021
2Transcription Factors (Transcription Factor)IBA
01/2022 - 10/2020
2DecitabineFDA Link
01/2021 - 01/2019
2ErbB Receptors (EGF Receptor)IBA
11/2020 - 12/2007
2taxaneIBA
11/2019 - 10/2008
2Phosphatidylinositols (Phosphatidylinositol)IBA
01/2019 - 06/2014
2Small Interfering RNA (siRNA)IBA
01/2017 - 05/2014
2Antineoplastic Agents (Antineoplastics)IBA
05/2014 - 10/2008
1Busulfan (Busulfex)FDA Link
02/2024
1fludarabineIBA
02/2024
1Methotrexate (Mexate)FDA LinkGeneric
01/2024
1Tacrolimus (Prograf)FDA LinkGeneric
01/2024
1Conditioned Culture MediaIBA
10/2023
1Chimeric Antigen ReceptorsIBA
01/2023
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
12/2022
1LisaftoclaxIBA
12/2022
1Mitochondrial Proteins (Mitochondrial Protein)IBA
11/2022
1ATPases Associated with Diverse Cellular ActivitiesIBA
11/2022
1Proteasome Endopeptidase Complex (Proteasome)IBA
11/2022
1GlucocorticoidsIBA
01/2022
1antineoplaston A10 (A 10)IBA
01/2022
1tofacitinibIBA
01/2022
1AlpelisibIBA
01/2021
1Transcription Factor AP-1 (Transcription Factor AP 1)IBA
01/2021
1Immune Checkpoint InhibitorsIBA
01/2021
1A-1331852IBA
01/2021
1ipatasertibIBA
01/2021
1Etoposide (VP 16)FDA LinkGeneric
01/2021
1ABT-414IBA
11/2020
1Immunoconjugates (Immunoconjugate)IBA
11/2020
1Histone MethyltransferasesIBA
10/2020
1tazemetostatIBA
10/2020
1Lysine (L-Lysine)FDA Link
10/2020
1Interleukin-3 Receptors (Interleukin 3 Receptor)IBA
11/2019
1UbiquitinIBA
11/2019
1Ligases (Synthetase)IBA
11/2019
1PlatinumIBA
11/2019
1tagraxofuspIBA
11/2019
1Thalidomide (Thalomid)FDA Link
11/2019
1copanlisibIBA
01/2019
1ProhibitinsIBA
01/2019
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2019
1Doxorubicin (Adriamycin)FDA LinkGeneric
01/2019
1Prednisone (Sone)FDA LinkGeneric
01/2019

Therapy/Procedure

53Therapeutics
01/2024 - 09/2002
26Drug Therapy (Chemotherapy)
01/2021 - 01/2007
10Precision Medicine
01/2023 - 12/2015
2Hematopoietic Stem Cell Transplantation
01/2024 - 09/2014
2Immunotherapy
01/2022 - 01/2021
2Aftercare (After-Treatment)
01/2020 - 08/2012
1Stem Cell Transplantation
02/2024
1Combination Drug Therapy (Combination Chemotherapy)
11/2019